TY - JOUR
T1 - Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer
AU - Guerrouahen, Bella S.
AU - Pasquier, Jennifer
AU - Abu Kaoud, Nadine
AU - Maleki, Mahtab
AU - Beauchamp, Marie Claude
AU - Yasmeen, Amber
AU - Ghiabi, Pegah
AU - Lis, Raphael
AU - Vidal, Fabien
AU - Saleh, Ahmed
AU - Gotlieb, Walter H.
AU - Rafii, Shahin
AU - Rafii, Arash
N1 - Publisher Copyright:
© 2014 AACR.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Ovarian cancer is the second leading cause of cancer-related death in women worldwide. Despite optimal cytoreduction and adequate adjuvant therapies, initial tumor response is often followed by relapse suggesting the existence of a tumor niche. Targeted therapies have been evaluated in ovarian cancer to overcome resistant disease. Among them, antiangiogenic therapies inhibit new blood vessel growth, induce endothelial cell apoptosis, and block the incorporation of hematopoietic and endothelial progenitor cells into new blood vessels. Despite in vitro and in vivo successes, antivascular therapy with bevacizumab targeting VEGF-A has limited efficacy in ovarian cancer. The precise molecular mechanisms underlying clinical resistance to anti-VEGF therapies are not yet well understood. Among them, tumor and stromal heterogeneity might determine the treatment outcomes. The present study investigates whether abnormalities in the tumor endothelium may contribute to treatment resistance to bevacizumab and promote a residual microscopic disease. Here, we showed that ovarian cancer cells activate Akt phosphorylation in endothelial cells inducing resistance to bevacizumab leading to an autocrine loop based on FGF2 secretion. Altogether, our results point out the role of an activated endothelium in the resistance to bevacizumab and in the constitution of a niche for a residual disease.
AB - Ovarian cancer is the second leading cause of cancer-related death in women worldwide. Despite optimal cytoreduction and adequate adjuvant therapies, initial tumor response is often followed by relapse suggesting the existence of a tumor niche. Targeted therapies have been evaluated in ovarian cancer to overcome resistant disease. Among them, antiangiogenic therapies inhibit new blood vessel growth, induce endothelial cell apoptosis, and block the incorporation of hematopoietic and endothelial progenitor cells into new blood vessels. Despite in vitro and in vivo successes, antivascular therapy with bevacizumab targeting VEGF-A has limited efficacy in ovarian cancer. The precise molecular mechanisms underlying clinical resistance to anti-VEGF therapies are not yet well understood. Among them, tumor and stromal heterogeneity might determine the treatment outcomes. The present study investigates whether abnormalities in the tumor endothelium may contribute to treatment resistance to bevacizumab and promote a residual microscopic disease. Here, we showed that ovarian cancer cells activate Akt phosphorylation in endothelial cells inducing resistance to bevacizumab leading to an autocrine loop based on FGF2 secretion. Altogether, our results point out the role of an activated endothelium in the resistance to bevacizumab and in the constitution of a niche for a residual disease.
UR - http://www.scopus.com/inward/record.url?scp=84917705793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84917705793&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-13-1053
DO - 10.1158/1535-7163.MCT-13-1053
M3 - Article
C2 - 25319392
AN - SCOPUS:84917705793
SN - 1535-7163
VL - 13
SP - 3123
EP - 3136
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 12
ER -